Late gadolinium enhancement (LGE) has been established as an independent predictor for adverse outcomes in hypertrophic cardiomyopathy (HCM). However, the prevalence and clinical significance of some LGE subtypes have not been well demonstrated.
 
Editors
Editor-in-Chief
Y.S. Chandrashekhar, MD, DM, FACC

CME Editor
Kenneth A. Ellenbogen, MD 

Author
Michael H. Beasley, MD, FACC

Important Dates
Date of Release: September 4, 2023
Term of Approval/Date of CME/MOC Expiration: September 3, 2024